Beyond RECIST: Molecular and functional imaging techniques for evaluation of response to targeted therapy

被引：126

作者：

Desar, I. M. E. ^{[1
]}

van Herpen, C. M. L. ^{[1
]}

van Laarhoven, H. W. M. ^{[1
]}

Barentsz, J. O. ^{[2
]}

Oyen, W. J. G. ^{[3
]}

van der Graaf, W. T. A. ^{[1
]}

机构：

[1] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, NL-6500 HB Nijmegen, Netherlands

[2] Radboud Univ Nijmegen, Med Ctr, Dept Radiol, NL-6500 HB Nijmegen, Netherlands

[3] Radboud Univ Nijmegen, Med Ctr, Dept Nucl Med, NL-6500 HB Nijmegen, Netherlands

来源：

CANCER TREATMENT REVIEWS | 2009年 / 35卷 / 04期

关键词：

Cancer; Targeted therapy; Molecular imaging; Functional imaging; ENDOTHELIAL GROWTH-FACTOR; POSITRON-EMISSION-TOMOGRAPHY; RECOMBINANT HUMAN ENDOSTATIN; ADVANCED COLORECTAL-CANCER; TYROSINE KINASE INHIBITOR; ASSESSING TUMOR RESPONSE; VEGF RECEPTOR INHIBITOR; RENAL-CELL CARCINOMA; PHASE-I TRIAL; LIVER METASTASES;

D O I：

10.1016/j.ctrv.2008.12.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The development of targeted therapies is a major breakthrough in the treatment of cancer. By evoking necrosis and cavitation, evaluation based on tumour size alone, as is done in the RECIST criteria, is no longer an adequate method. New molecular and functional imaging techniques are developed. This review focuses on the use of new imaging modalities for the evaluation of treatment response of pathway based targeted therapies. First, the basic principles of functional and molecular imaging modalities are briefly discussed. Thereafter, their clinical application in targeted therapies is correlated to the underlying biological mechanism. in this way, the best method for response evaluation for a new agent can be identified. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：309 / 321

页数：13

共 132 条

[1]

Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: Quality and analysis results of a phase I trial [J].

Akella, NS ;

Twieg, DB ;

Mikkelsen, T ;

Hochberg, FH ;

Grossman, S ;

Cloud, GA ;

Nabors, LB .

JOURNAL OF MAGNETIC RESONANCE IMAGING, 2004, 20 (06) :913-922

[2]

Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate [J].

Anderson, HL ;

Yap, JT ;

Miller, MP ;

Robbins, A ;

Jones, T ;

Price, PM .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) :2823-2830

[3]

AVADHANI AD, 2008, J CLIN ONCOL

[4]

AZAD NS, 2007, J CLIN ONCOL, pS18

[5]

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [J].

Batchelor, Tracy T. ;

Sorensen, A. Gregory ;

di Tomaso, Emmanuelle ;

Zhang, Wei-Ting ;

Duda, Dan G. ;

Cohen, Kenneth S. ;

Kozak, Kevin R. ;

Cahill, Daniel P. ;

Chen, Poe-Jou ;

Zhu, Mingwang ;

Ancukiewicz, Marek ;

Mrugala, Maciej M. ;

Plotkin, Scott ;

Drappatz, Jan ;

Louis, David N. ;

Ivy, Percy ;

Scadden, David T. ;

Benner, Thomas ;

Loeffler, Jay S. ;

Wen, Patrick Y. ;

Jain, Rakesh K. .

CANCER CELL, 2007, 11 (01) :83-95

[6]

Benatsou B, 2008, J CLIN ONCOL, V26

[7]

Vascular remodeling and clinical resistance to antiangiogenic cancer therapy [J].

Bender, JG ;

Cooney, EM ;

Kandel, JJ ;

Yamashiro, DJ .

DRUG RESISTANCE UPDATES, 2004, 7 (4-5) :289-300

[8]

Platelet-derived growth factor receptor (PDGFR): A target for anticancer therapeutics [J].

Board, R ;

Jayson, GC .

DRUG RESISTANCE UPDATES, 2005, 8 (1-2) :75-83

[9]

Multimodality molecular imaging of tumor angiogenesis [J].

Cai, Weibo ;

Chen, Xiaoyuan .

JOURNAL OF NUCLEAR MEDICINE, 2008, 49 :113S-128S

[10]

Imatinib mesylate in chordoma [J].

Casali, PG ;

Messina, A ;

Stacchiotti, S ;

Tamborini, E ;

Crippa, F ;

Gronchi, A ;

Orlandi, R ;

Ripamonti, C ;

Spreafico, C ;

Bertieri, R ;

Bertulli, R ;

Colecchia, M ;

Fumagalli, E ;

Greco, A ;

Grosso, F ;

Olmi, P ;

Pierotti, MA ;

Pilotti, S .

CANCER, 2004, 101 (09) :2086-2097

← 1 2 3 4 5 6 7 8 9 10 →